Clinical Trials Update: April 24, 2006
Schizophrenia and Schizoaffective Disorders Excessive Sweating Myelodysplastic Syndromes (MDS)
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Schizophrenia and Schizoaffective Disorders
This study will compare an investigational agent to a marketed medication in the treatment of people with negative symptoms of schizophrenia. Volunteers 18 and older who have a current primary diagnosis of negative symptoms of schizophrenia and have been clinically stable for the past five months may qualify.
The research sites are located across the United States.
This study will evaluate whether an investigational drug reduces underarm sweat. Candidates 12-17 who have axillary hyperhidrosis (excessive armpit sweating) without an underlying medical cause and have had no previous treatment with botulinum toxin type A (Botox) may qualify.
The research site is in San Diego, Calif.
Myelodysplastic Syndromes (MDS)
Novartis Oncology is evaluating whether the study drug deferasirox is safe and effective when given to people with myelodysplastic syndrome (MDS). Candidates 18 or older must be diagnosed with myelodysplastic syndrome (MDS) with iron overload and have had a minimum of 20 blood transfusions.
Research sites are located throughout the United States.
Copyright 2006 CenterWatch. All rights reserved.